Overview
The ABCs of CTD-PAH: (A)lgorithms, Team - (B)ased Approach, and (C)ombination Therapy
CTD-PAH Expert Interview
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, rheumatologists, and other AHPs treating patients with PAH
Pulmonary arterial hypertension (PAH) is a progressive disorder of the small pulmonary arteries characterized by endothelial dysfunction and vascular remodeling that results in increased pulmonary vascular resistance and pulmonary pressures, and is a highly challenging condition to both diagnose and manage. Connective tissue disease-associated PAH (CTD-PAH) is the second most common cause of PAH, accounting for approximately 25% of cases, and is associated with worse outcomes than idiopathic PAH.
Given the impact on patient outcomes, screening of PAH in CTD patients, including those with systemic sclerosis (scleroderma), systemic lupus erythematosus, and mixed CTD, is of critical importance. However, even with appropriate screening to identify suspected cases of CTD-PAH, the diagnosis of PAH in these patients is challenging due to the complex differential diagnosis. In addition, treatment selection is complex due to comorbidities, relatively little clinical trial data in this patient population, and evidence suggesting attenuated responses to PAH therapies in CTD-PAH patients.
Therefore, clinicians require education on the detection, diagnosis, and treatment of CTD-PAH, taking into account the particular clinical nuances relevant to this patient population. Clinicians must be prepared to adapt their practices to include better screening practices, selection of appropriate treatments, and multidisciplinary collaboration to ensure effective management of CTD-PAH patients to improve outcomes.
Upon completion of this activity, participants will be able to:
• Discuss the impact that various screening protocols have on CTD-PAH patient outcomes.
• Outline steps involved in the differential diagnosis of CTD-PAH
• Formulate comprehensive management plans for patients with CTD-PAH
• Discuss the impact that various screening protocols have on CTD-PAH patient outcomes.
• Outline steps involved in the differential diagnosis of CTD-PAH
• Formulate comprehensive management plans for patients with CTD-PAH
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, UT
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, UT
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Advisory Board: Bayer and Janssen PH
Consultant: Vertex
Speakers Bureau: Bayer, Janssen PH, United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: sotatercept and GB002 (seralutinib)
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view all four online chapters and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
